| Date | Title | Description |
| 13.01.2022 | PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome | PITTSBURGH, Jan. 13, 2022 /PRNewswire/ -- PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for... |
| 12.01.2022 | Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update | ~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, t... |
| 24.05.2021 | XERIS PHARMACEUTICALS, INC.
XERIS PHARMACEUTICALS : TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES (Form 8-K) | XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES
Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial ... |
| 24.05.2021 | XERIS PHARMACEUTICALS : TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES (Form 8-K) | XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES
Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial ... |
| 03.12.2018 | 5 Startup Trends that Shaped the Midwest in 2018
1. Marketplaces remain one of the strongest tech sectors
2. Health care gets even hotter
3. Logistics keeps on truckin’
4. Big bets on enterprise s... | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. Just this week, celebrity shoutout marketplace startup Cameo announced that it closed a $12.5 million round of funding led by Lightspeed Vent... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. Just this week, celebrity shoutout marketplace startup Cameo announced that it closed a $12.5 million round of funding led by Lightspeed Vent... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
2018 is quickly drawing to its close, but the Mid... |
| 05.10.2018 | Chicago’s Startups Continue to Lead the Nation in Returns | PitchBook revealed its 2018 Chicago VC Ecosystem report, released in conjunction with ChicagoNEXT’s Chicago Venture Summit. This report finds that Chicago continues to outpace other U.S. venture ecosystems — including the Bay Area — in medi... |
| 03.10.2018 | Chicago’s startups continue to lead the nation in returns | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Today, PitchBook revealed its 2018 Chicago VC Eco... |
| 03.10.2018 | Chicago’s startups continue to lead the nation in returns | Today, PitchBook revealed its 2018 Chicago VC Ecosystem report, released in conjunction with ChicagoNEXT’s Chicago Venture Summit. This report finds that Chicago continues to outpace other U.S. venture ecosystems — including the Bay Area — ... |
| 25.05.2018 | Xeris Pharmaceuticals Files to Raise $75 Million in an IPO | Xeris Pharmaceuticals, founded in 2005 in Austin, filed on Thursday with the Securities and Exchange Commission to go public on the Nasdaq Stock Exchange with an initial public offering valued at $75 million. |
| 19.05.2017 | Xeris Pharmaceuticals Closes $30M Financing |
AUSTIN, TX, Merieux Developpement has recently concluded an equity investment into Xeris Pharmaceuticals.
>> Click here for more funding data on Xeris Pharmaceuticals
>> To export Xeris Pharmaceuticals funding data to PDF an... |
| 18.05.2017 | Xeris Pharmaceuticals Closes $30 Million Financing | CHICAGO, IL and AUSTIN, TX, May 17, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of ready-to-use injectable drugs, today a... |
| 01.09.2016 | Ten Life Science Startups to Watch in Austin | |
| 08.01.2016 | Xeris Pharmaceuticals Closes $41M Series C Financing | Xeris Pharmaceuticals, Inc., an Austin, Texas-based specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs, closed a $41m Series C financing.
The round was led by the R... |
| 07.01.2016 | Xeris gets $41M for shelf-stable glucagon pen | “The current emergency kit on the market involves dry powder in a vial that has to be manually mixed up and is a nine-step process,” Douglas Baum, CEO of Xeris, told the Austin American-Statesman. “Ours is premixed and is sort of an EpiPen ... |
| 07.01.2016 | Daily funding roundup - January 7, 2016 | Guardant Health raised $100M; Founders Fund invested $52M in NuBank; Sisense received $50M funding
IQuity Labs, a Nashville, TN-basedbiotechnology company specializing in diagnostic tests for autoimmune disease and related conditions, secur... |
| 29.09.2014 | Xeris developing glucagon product for diabetes control, raises $7.2M | While tremendous advances have been made in the development of insulin and insulin analogs to manage hyperglycemia (high blood sugar), very little progress has been made in the development of glucagon products to manage hypoglycemia.
It’s a... |
| 29.01.2014 | Austin Technology Incubator Celebrates 25 Years and Graduates 25 Companies | The Austin Technology Incubator celebrates its 25 anniversary and plans to graduate its latest crop of 25 companies during an event Wednesday night at the AT&T Executive Education and Conference Center.
The ATI, part of IC2 Institute at... |
| 13.02.2013 | Xeris Pharmaceuticals Lands $6 Million More in Funding | Xeris Pharmaceuticals of Austin has raised an additional $6 million.
The pharmaceutical company has developed injectable treatments for diabetes, epilepsy and other diseases.
Xeris raised its money from private foundations, federal governme... |
| 01.10.2012 | Insights on Pitches at CTAN’s Power of Angel Investing. | Editor’s note: Michael Girdley is a contributor to Silicon Hills News. He’s also a startup investor. He attended the Central Texas Angel Network Demo Day last weekend. These are his impressions from the event. |
| 13.06.2012 | EpiPen-style glucagon for hypoglycemia headed to phase 2 trials this summer | A phase 2 clinical trial with the School of Medicine at The University of Texas Health Science Center San Antonio and the Texas Diabetes Institute of the University Health System in San Antonio will start in August, and according to a memor... |
| 12.12.2011 | Xeris Pharmaceuticals Completes $1.5m Series A Financing | Xeris Pharmaceuticals, Inc., an Austin, TX-based biopharmaceutical company developing the a glucagon rescue pen for emergency treatment of severe hypoglycemia, has completed a $1.5m Series A financing.
The round was led by the Central Texas... |
| - | Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma | CHICAGO–(BUSINESS WIRE)–Dec. 16, 2021– Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, tod... |
| - | Top biotech analysts say these 18 companies are set to run out of cash within a year | Henry Ji, the CEO of Sorrento Therapeutics. Mike Blake/Reuters This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Biotech companies with dwindling levels of cash are struggling to navigate a... |
| - | Xeris developing glucagon product for diabetes control, raises $7.2M | An Austin-based company that’s developing the blood sugar-regulating hormone glucagon, as opposed to insulin, is in the midst of a decent-sized Series B deal.
Xeris Pharmaceuticals has raised $7.2 million in Series B funding, according to a... |
| - | EpiPen-style glucagon for hypoglycemia headed to phase 2 trials this summer | A number of companies are in the race to develop stable formulations of glucagon that would replace the multistep, syringe-and-vial approach to treating hypoglycemic episodes in diabetics. One of them that’s developed a low-volume formulati... |
| - | Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14 | CHICAGO–(BUSINESS WIRE)–May 12, 2022– Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, toda... |
| - | Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above | First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue
CHICAGO–(BUSINESS WIRE)–Mar. 16, 2022– Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing ... |
| - | Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital | $100M drawn down at close; repayment of existing term loan; near-term access to an additional $50M
Provides significant operating and financial flexibility
Cash flow breakeven expected by year-end 2023
CHICAGO–(BUSINESS WIRE)–Mar. 10, 20... |
| - | Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update | Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020
Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million
20+ mil... |
| - | Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 | CHICAGO–(BUSINESS WIRE)–Mar. 4, 2022– Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, toda... |
| - | Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome | FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev to be a safe and effective therapeutic option in the treatment of Cushing’s syndrome
FDA decision follows successful compl... |
| - | Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events | Launched Recorlev® and Gvoke® Kit
Achieved Q1 net product revenue of $21.9M – a 33% increase from same period prior year on a pro forma basis
Ended Q1 with $132.1M in cash, cash equivalents and short-term investments
Affirming 2022 guida... |
| - | Xeris gets $41M for shelf-stable glucagon pen | Austin-based specialty drug startup Xeris Pharmaceuticals just closed a $41 million Series C round to advance its G-Pen – a shelf-stable glucagon product for diabetics with severe hypoglycemia.
The new formulation is in the midst of Phase 3... |
| - | Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021 | CHICAGO–(BUSINESS WIRE)–Nov. 2, 2021– Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, toda... |
